Get started
Author

Reginald Lassagne

Observed names: R. Lassagne, Reginald Lasagne
ORCID: 0009-0003-9280-6342
Observed ORCID: 0009-0003-9280-6342
OpenAlex ID: A5022536531
Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011–2021
2024 · Rohit Shankar, Xiaocong Li Marston, et al. · Journal of Neurology · 34
PDF
Comparison of utilization and cost of healthcare services and pharmacotherapy following implantation of vagus nerve stimulation vs. responsive neurostimulation or deep brain stimulation for the treatment of drug-resistant epilepsy: analyses of a large United States healthcare claims database
2022 · Tom Vincent, Qian Li, et al. · Journal of Medical Economics · 15
Patterns of utilization and cost of healthcare services and pharmacotherapy among patients with drug-resistant epilepsy during the two-year period before neurostimulation: A descriptive analysis of the journey to implantation based on analyses of a large United States healthcare claims database
2023 · Kathryn Evans, Nicole Stamas, et al. · Epilepsy & Behavior · 10
PDF
Impact of Vagus Nerve Stimulation for the Treatment of Drug-resistant Epilepsy on Patterns of Use and Cost of Health Care Services and Pharmacotherapy: Comparisons of the 24-Month Periods Before and After Implantation
2023 · Kathryn Evans, Nicole Stamas, et al. · Clinical Therapeutics · 7
Use of Healthcare Claims Data to Generate Real-World Evidence on Patients With Drug-Resistant Epilepsy: Practical Considerations for Research
2024 · Nicole Stamas, Tom Vincent, et al. · Journal of health economics and outcomes research · 5
Impact of Vagus Nerve Stimulation for the Treatment of Drug-resistant Epilepsy on Patterns of Use and Cost of Healthcare Services and Pharmacotherapy Among Medicare Enrollees: Findings From Analyses of Healthcare Claims From the Centers of Medicare and Medicaid Services
2025 · Kathryn Evans, Qian Li, et al. · Clinical Therapeutics · 3
Healthcare Utilization and Cost in the Two Years Before Neuromodulation Implantation Among Medicaid Enrollees with Drug-Resistant Epilepsy
2025 · Kathryn Evans, Qian Li, et al. · ClinicoEconomics and Outcomes Research · 2
PDF
Initiating Patients on Peritoneal Dialysis Compared with In-Centre Haemodialysis in the United Kingdom: A Cost-Utility and Budget Impact Analysis
2026 · Tara Danying Li, Claudia Rinciog, et al. · PharmacoEconomics - Open
PDF
Estimated Demand Does Not Explain Variation in Peritoneal Dialysis Use: A National Facility-Level Analysis
2026 · Reginald Lassagne · Journal of the American Society of Nephrology
Real-World Analysis of the Association Between Kidney Disease Education (KDE) and Peritoneal Dialysis (PD)
2026 · Firas Dabbous, Julie Brown, et al. · Journal of the American Society of Nephrology
Estimating the Cost-Effectiveness of Peritoneal Dialysis Compared with Hemodialysis as a Starting Modality in the United States
2026 · Araadhna Sinha, Eric Adam Simonic, et al. · Journal of the American Society of Nephrology
Estimating the Budget Impact of Peritoneal Dialysis Compared with Hemodialysis in the United States
2026 · Araadhna Sinha, Eric Adam Simonic, et al. · Journal of the American Society of Nephrology
HSD89 The Patient Journey Prior to Neuromodulation in Drug-Resistant Epilepsy, Patterns of Utilization and Cost of Healthcare Services and Pharmacotherapy Based on a Claim Database in the United States
2023 · R. Lassagne, L. Zhang, et al. · Value in Health
PDF
Works count: 13
Citation count: 76
H-index: 5
I10-index: 3
Year
Topic
Type